Mark Arnold Hagler files SEC Form 4 disclosures for NovaBridge Biosciences. They have made 1 open-market trade across 1 company since 2026, most recently 2026-04-24.
CIK 0002126029
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $577K since 2026, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NBP | 230,000 | $292K |
Shares reported on the most recent Form 4, priced at the 2026-04-28 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBP | BUY | 2026-04-24 | 2026-04-28 | $2.51 | $577K | -17.0% | -28.7% | -32.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.